Skip to content
thestock.space

As of 6 Nov 2026, Torrent Pharmaceuticals trades at 80.2× trailing earnings, above the industry P/E of 28.7×. Sales and net profit grew 13% and 20% a year over 3 years; its ROCE of 9.1% is the lowest among the 7 largest Drug Manufacturers (Specialty & Generic) peers. Debt is 0.77× equity, and its dividend yield is 0.8%. It is a large-cap company with a market cap of ₹1.8 lakh crore, ranked 3rd of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares rose 32% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Sep 2026.How we calculate this

past year
Open
₹4,733.60
Day high
₹4,789.50
Day low
₹4,699.10
Prev. close
₹4,710.00
Volume
3.6 L

Health check

2 good · 1 fair · 3 to check
  • ReturnsAhead

    +31.7% over a year, better than 5 of 7 peers.

  • Price tagPricier

    P/E 80.2 vs industry 28.7.

  • GrowthStrong

    Sales +13.3%, profit +20.2% a year over 3 years.

  • ProfitabilityWeak

    ROCE 9.1% vs peer median 17.9%.

  • Balance sheetFair

    Debt 0.77× equity, interest covered 8.5×, Piotroski 4 of 9.

  • Red flags2 to check

    P/E of 80.2 against an industry P/E of 28.7.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Large cap

₹1.8L Cr, #3 of 154 in its industry by size.

Market sensitivity

Measuring against the NIFTY 50…

Key metrics

Last 12 months to Sep 2026: sales ₹17,400 Cr · profit ₹2,124 Cr
Market cap
₹1.8L Cr
Large cap
P/E
80.2
Industry 28.7
Price to book
9.83
Peers 4.99
Dividend yield
0.80%
ROE
15.7%
Peers 13.6%
ROCE
9.1%
Peers 17.9%
Debt to equity
0.77
Debt ₹14,107 Cr
EPS (TTM)
₹59.20
Face value ₹5
OPM (TTM)
33.7%
Net margin 12.2%
Sales growth
+50.8%
Latest quarter vs a year ago
Profit growth
−9.6%
Latest quarter vs a year ago
Price to sales
10.38
EV/EBITDA 33.6

Strengths and risks

Strengths

  • Quarterly sales up 50.8% on a year ago.
  • Positive operating cash flow in each of the last 4 years.

Risks to check

  • P/E of 80.2 against an industry P/E of 28.7.
  • Promoter stake down from 68.3% to 60.8%.

Derived automatically from reported figures. Not a recommendation.

About Torrent Pharmaceuticals

Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, marketing, and distribution of branded and generic pharmaceutical formulations in India, the United States, Brazil, Germany, Malta, and internationally. The company offers products in various therapeutic areas, including anti-diabetic, anti-microbial, cardiovascular, CNS, urology, gynecology, oncology, gastro-intestinal, nephrology, neuro-psychiatric, dermatology,…

Headquarters
Ahmedabad
Employees
18,258
Sector
Healthcare
ISIN
INE685A01028
Website
torrentpharma.com

Price range

52 weeks

₹3,602.00₹5,250.00

Today

₹4,699.10₹4,789.50
Avg volume (3M)
3.3 L
1-year return
plus 31.7%
From 52-week high
minus 9.5%

Analyst consensus

28 analysts
BuyMean target ₹5,472.79 plus 15.2%

Target range, with today’s price

Low ₹4,545.00High ₹6,478.00

Consensus from Yahoo Finance. Not a recommendation.

Peers · Drug Manufacturers - Specialty & Generic

Compare with peersScreen the whole industry
Company
SUNPHARMASun Pharmaceutical Industries1,860.00plus 1.69%4,46,27640.74.9917.9%13.1%28.2%10.4%10.6%0.86%plus 8.2%
DIVISLABDivi's Laboratories10,320.50plus 1.78%2,73,97793.616.3519.0%16.2%34.9%11.0%12.1%0.29%plus 49.0%
TORNTPHARMTorrent Pharmaceuticals4,750.00plus 0.85%1,80,67580.29.839.1%15.7%33.7%13.3%20.2%0.80%plus 31.7%
LAURUSLABSLaurus Labs2,340.00minus 0.26%1,26,43394.420.8619.5%24.0%30.4%3.8%4.0%0.09%plus 138.6%
ZYDUSLIFEZydus Lifesciences1,197.90plus 0.41%1,19,49128.64.2919.0%14.7%26.2%16.5%37.0%0.08%plus 22.8%
DRREDDYDr. Reddy's Laboratories1,373.00plus 0.51%1,14,46240.92.9614.2%7.3%15.9%11.0%−1.7%0.58%plus 13.8%
CIPLACipla1,411.00plus 0.49%1,13,99339.43.2214.9%8.3%17.3%7.2%11.5%0.92%minus 6.6%
MANKINDMankind Pharma2,540.00plus 0.87%1,04,91346.85.9713.7%13.6%26.5%17.7%14.3%0.00%plus 6.3%
Median of 7 peers–0.51%1,19,49140.94.9917.9%13.6%26.5%11.0%11.5%0.29%13.8%

Quarterly results

Consolidated, ₹ crore
SalesSelect a row below to chart it
₹ CrSep 25Dec 25Mar 26Jun 26Sep 26
3,2463,2514,1284,8354,896
2,1632,1632,7723,1713,230
1,0831,0881,3561,6641,666
33.4%33.5%32.8%34.4%34.0%
−27−13−17−12−10
4845236305300
204206508593609
−13−10−66−21−10
791814529733737
25.3%22.0%31.2%22.8%27.5%
591635389566534
17.4518.7711.5114.8714.05

Profit & loss

Yearly, ₹ crore
Sales CAGR 3Y
+13.3%
Profit CAGR 3Y
+20.2%
EPS CAGR 3Y
+20.2%
ROE
15.7%
Net profitSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
9,46410,56211,31713,753
–+11.6%+7.1%+21.5%
6,6227,1957,5969,194
2,8423,3683,7214,559
30.0%31.9%32.9%33.1%
2.8394.3−143
332353251385
7027957951,119
36.693.4−6.1−40.3
1,8472,3522,6732,872
32.6%29.6%28.5%25.6%
1,2451,6561,9112,163
–+33.0%+15.4%+13.2%
36.7948.9456.4763.92

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore
Total assetsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
169169169169
6,0296,6877,4218,219
5,3694,0223,20215,026
3,4454,1824,19720,898
15,01215,06114,99044,312
3,4823,5933,8655,394
711296409486
71.133.344.699.4
7231,0046882,355
10,02510,1349,98335,978
15,01215,06114,99044,312

Cash flow

Yearly, ₹ crore
Cash from operationsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
2,3683,2662,5853,023
−2,415−168−540−12,712
77.4−2,780−2,29810,151
30.2319−253461
−574−433−612−677
1,7942,8331,9732,345
−863−1,015−1,083−1,289

Shareholding pattern

Source: NSE filings
60.8%
promoters
  • Promoters60.78%
  • Public39.22%
  • As of 30 Sep 2026
QuarterSplitPromotersPublicPromoter change
30 Sep 202660.78%39.22%0.00
20 Jul 202660.78%39.22%minus 7.53
30 Jun 202668.31%31.69%0.00
31 Mar 202668.31%31.69%0.00
31 Dec 202568.31%31.69%–

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you